Supply of extemporaneous medicines and their active ingredients

This tender for extemporaneous medicines and active substances is primarily driven by price. A winning strategy will focus on a highly competitive price, meticulous adherence to all technical and contractual requirements, and demonstrating robust supply chain reliability. While social value and innovation are absent, demonstrating operational excellence and a commitment to quality will be crucial differentiators.

Uncompromising Quality and Reliability at the Lowest Price

Streamlined Supply Chain for Consistent Availability

Expertise in Extemporaneous Medicine Sourcing and Delivery

Submit the absolute lowest viable price that ensures profitability. Conduct a detailed cost breakdown to identify all areas for optimization. Benchmark against industry standards for similar supplies.

Thoroughly review and ensure strict adherence to all mandatory exclusion grounds and eligibility requirements outlined in 'Iepirkuma priekšmeta prasības, 1.versija' and '01_Pieteikums (forma)'. Any deviation can lead to immediate disqualification.

Given that price is the sole evaluation criterion, develop a highly competitive financial offer. This requires a detailed understanding of cost structures and potential efficiencies in sourcing, production, and logistics.

Ensure the technical proposal and the offered products precisely meet all specifications detailed in '02_Tehniskā specifikācija_finanšu piedāvājums' and 'Iepirkuma priekšmeta prasības, 1.versija'. Document any minor deviations and their justifications clearly.

Carefully review the draft supply contract ('03_Piegādes līguma projekts') and general agreement ('04_Vispārīgās vienošanās projekts') to understand all obligations, particularly regarding delivery terms, quality assurance, and payment terms. Identify any potential risks or areas for clarification.

Submit the bid well in advance of the deadline (2026-02-23T10:00:00) to account for any unforeseen technical issues with the submission portal or last-minute document checks.

While not explicitly evaluated, subtly emphasize the reliability and efficiency of your supply chain in the technical proposal. This can build confidence in your ability to consistently meet demand, especially if competitors have a history of supply issues.

This tender for extemporaneous medicines demonstrates good clarity and structured requirements but is significantly hampered by the undisclosed estimated value and restricted document access, raising serious concerns about fairness and legal compliance.

The tender defines the procedure type and CPV codes correctly, and the submission deadline is reasonable. However, the estimated value is not disclosed, and there is a flag for restricted document access, which are significant issues impacting transparency and legal compliance.

The tender description is clear, and requirements are well-documented and referenced across specific documents. Evaluation criteria (lowest price) are explicitly stated, contradicting the automated check, and performance conditions are outlined in draft contracts.

Basic information, deadlines, duration, and location are provided. All necessary documents are listed and summarized, and requirements are extensively defined. However, the estimated value of the contract is not disclosed, which is a notable gap.

The evaluation criteria (lowest price) are objective, and requirements appear generic. However, the undisclosed estimated value and, critically, the restricted document access severely undermine the fairness and equal opportunity for all potential bidders.

E-procurement is indicated, and the contract duration is clear. Nevertheless, the lack of an estimated value and the restricted document access make it difficult for bidders to assess the opportunity and prepare effectively. No explicit contract start date is provided.

Dates are logical, and there are no disputes. However, the estimated value is missing, and there's a contradiction between 'Documents available' and 'Restricted document access', indicating an inconsistency in accessibility.

The tender does not include any specific green procurement, social aspects, or innovation focus, nor is it indicated as EU funded.